ORAL Presentations - Monday, June 16

Monday, June 16

Roosevelt Room

10:45-12:15
OR01 - ECONOMIC CONSIDERATIONS OF SELECTED INTERVENTIONS #1 
Moderator: Barbara Gad, Poland
10:45 OR1.1 - Economics Determinants of Physical Activity Participation of Women in Brazil and the Implications for Obesity
Giácomo Balbinotto, Brazil 		 
11:00 OR1.2 - Cost Evaluation of a CPAP Funded Policy for the Treatment of Obstructive Sleep Apnea in Quebec
Eric Potvin, Canada 		 
11:15 OR1.3 - Bortezomib improves effectiveness of treatment of multiple myeloma with considerable budget impact
Agnes Männik, Estonia 		 
11:30 OR1.4 - Use of HTA in developing public policies for effective illicit drug prevention programs
Marina Gonçalves de Freitas, Brazil 		 
11:45 OR1.5 - Offering relevant services for high burden conditions: what is the economic evidence?
David Paul Lindhard-Tordrup, Belgium 		 
12:00 OR1.6 - Economics of Diabetes Mellitus: theory and evidence for Brazilian data – 2008
Giácomo Balbinotto, Brazil 		 
     

Monday, June 16

Cabin John Room

10:45-12:15
OR02 - SYSTEMATIC REVIEWS OF SELECTIVE INTERVENTIONS #1
Moderator: Tammy Clifford, Canada
10:45 OR2.1 - The Diagnostic Value of Fluor-18-deoxyglucose(18F-FDG) PET or PET/CT for Hepatocellular carcinoma: A Systematic Review and Meta-analysis
Jinkyung Park, Korea 		 
11:00 OR2.2 - Robotically-assisted coronary artery bypass grafting (CABG) surgery: a systematic review and meta-analysis
Anna Maria Buehler, Brazil 		 
11:15 OR2.3 - Self-sampling devices in HPV-based cervical cancer screening. A systematic review to assess the effect on Participation
Paolo Giorgi Rossi, Italy 		 
11:30 OR2.4 - Cost-effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review
Jinsong Geng, China 		 
11:45 OR2.5 - Systematic review of economic evaluation of prenatal screening for Down’s syndrome
Yuan Huang, China 		 
12:00 OR2.6 - Urea for the management of the Syndrome of Inappropriate Secretion of ADH: a systematic review
Oriol Solà-Morales, Spain 		 
     

Monday, June 16

Renwick + Bulfinch Room

10:45-12:15
OR03 - APPLICATION OF HTA AROUND THE WORLD
Moderators: Tommy Wilkinson, United Kingdom & Hector Castro, Columbia
10:45  OR3.1 - A novel integrated rapid access to assessment and treatment model of care using FibroScan for patients with chronic virus hepatitis in Queensland, Australia
Linda Mundy, Australia 		 
11:00  OR3.2 - Health technology assessment of pulse wave velocity and ankle brachial index: reimbursed by the health insurance in Shanghai or waiting for further evidence?
Yiwei Mao, China 		 
11:15  OR3.3 - Promoting Patient’s medication safety through SMS media campaigns, The AIDS Support Organization (TASO) Uganda, Experience
Justine Negesa, Uganda 		 
11:30  OR3.4 - Assessment of the fast track surgery for Kazakhstan
Temirkhan Kulkhan, Kazakhstan 		 
11:45  OR3.5 - Patient Safety Climate in Secondary General Public Hospitals in Shanghai
Ping Zhou, China 		 
12:00  OR3.6 - Implementing community based support for people with severe mental illness – experiences from Denmark
Ulla Vaeggemose, Denmark 		 
     

Monday, June 16

Latrobe Room

10:45-12:15
 OR04 - HOSPITAL-BASED HTA #1
Moderators: Americo Cicchetti, Italy & Laura Sampietro, Spain
10:45  OR4.1 - Modern Dressings and Skin Grafting in the Management of Diabetic Foot Ulcers in Cipto Mangunkusumo Hospital Jakarta Indonesia
Respati W. Ranakusuma, Indonesia 		 
11:00  OR4.2 - Assessing the effectiveness of electronic documentation in Australian nursing homes
David Hailey, Australia 		 
11:15  OR4.3 - Health Technology Assessment (HTA) in a Community Hospital: Lessons from the Learning Curve
David Parés, Spain 		 
11:30  OR4.4 - Health Technology Assessment of Rehabilitation Hospital: A Review
Alireza Olyaeemanesh, Iran 		 
11:45  OR4.5 - Early Results of AdHopHTA and potential contribution to development of HTA in Turkey
Rabia Kahveci, Turkey 		 
12:00  OR4.6 - Bridging hospital-based and regional/national HTA in Norway
Brynjar Fure, Norway 		 
     

Monday, June 16

Burnham Room

10:45-12:15
 OR05 - IMPROVING TREATMENT OPTIONS
Moderator: Marc Rhainds, Canada
10:45  OR5.2 - Nadroparin in the treatment of patients with pulmonary embolism (PE)
Gabriela Vilela Brito, Brazil 		 
11:00  OR5.3:  Clinical effectiveness of art therapy in people with non-psychotic mental health disorders:  Health Technology Assessment for the National Institute for Health Research, UK
Lesley Uttley, United Kingdom 		 
11:15  OR5.4 - Eculizumab (Soliris®) for the Paroxysmal Nocturnal Haemoglobinuria: a Rapid Review
Betania Ferreira Leite, Brazil 		 
11:30  OR5.5 - Equal access to treatment in elderly patients with acute myocardial infarction: a case study in a Shanghai hospital
Na Li, China 		 
11:45  OR5.6 - A comparative study of semiautomated defibrillators for in-hospital early defibrillation
Federico Nocchi, Italy 		 
     

Monday, June 16

Farragut Square Room

10:45-12:15
 OR06 - PROCESS OF HTA - EXPERIENCES FROM DIFFERENT COUNTRIES
Moderators: David Banta, France & Paulo Picon, Brazil
10:45  OR6.1 - Web 2.0 Utilization in Health Technology Assessment Agencies of Euroscan
Iñaki Gutiérrez-Ibarluzea, Spain 		 
11:00  OR6.2 - Does HTA affect decisions and clinical practice - case studies from SBU
Måns Rosén, Sweden 		 
 11:15  OR6.5 - Evaluating implementation strategies – Modelling the link between information and implementation dynamics using data obtained from elicitation of expert opinions
Sabine Elisabeth Grimm, United Kingdom 		 
     

Monday, June 16

Lafayette Park Room

10:45-12:15
 OR07 - HOW TO IMPROVE RESOURCE ALLOCATION
Moderators: Neale Smith, Canada & Arianna Waye, Canada
10:45  OR7.1 - Korean Cost-effectiveness Threshold Revisited - Asian Collaborative Study
Jeonghoon Ahn, Korea 		 
11:00  OR7.2 - Audit of adherence to health technology assessment guidance for new procedures with an uncertain evidence base
Hannah Patrick, United Kingdom 		 
11:15  OR7.3 - Differences and Similarities of Models for the Identification of Ineffective Interventions: Deriving Good Practice Recommendations Based on International Experiences
Julia Mayer, Austria 		 
11:30  OR7.4 - Impact of Essential Health Benefit Benchmark Plans on Patient Choice and Health Outcomes: Analysis of CMS 2014 Plans for Top Five States
Saurabh (Rob) Aggarwal, USA 		 
11:45  OR7.5 - Health Technology Assessment (HTA) in Switzerland: The “SwissHTA” Multi-Stakeholder Consensus
Michael Schlander, Germany 		 
12:00  OR7.6 - Equity considerations among HTA agencies – current practice and ways forward
Dimitra Panteli, Germany 		 
     

Monday, June 16

Franklin Square Room

10:45-12:15
 OR08 - PATIENTS-CENTRED CARE #1
Moderator: Marc Boutin
10:45  OR8.1 - Narrative reviews - one way of putting patients and relatives in the centre
Bente Hoeck, Denmark 		 
11:00  OR8.2 - Types of outcomes (intermediate/disease-oriented vs. patient-oriented) used in guideline development by various guideline-making bodies around the world
Chisato Hamashima, Japan 		 
11:15  OR8.3 - Coalition Building towards effective  Patient entered Health Care
John Vianney Amanya, Uganda 		 
11:30  OR8.4 - Patients Matter: Engaging Patients as Collaborators to Improve Osteoarthritis (OA) Care in Alberta
Deborah A Marshall, Canada 		 
11:45  OR8.5 - Electronic personal health records in Canada: priority issues for implementation
Julie Payne-Gagnon, Canada 		 
12:00  OR8.6 - How to put patients in the centre when developing Clinical Practice Guidelines (CPG)?
Giselle Balaciano, Argentina 		 
     

Monday, June 16

McPherson Square Room

10:45-12:15
 OR09 - ACCESS TO MEDICINES
Moderator: Monika Wagner, Canada
10:45  OR9.1 - Access to Medicines, the High Cost of the Universal Health System: The Case of Pegylated Interferon
Joseneide Santos Queiroz, Brazil 		 
11:00  OR9.3 - HTA and orphan drugs: to what extent do disease and treatment characteristics influence HTA-based recommendations, and could these indicate whether orphan drugs have a “special status”?
Elena Nicod, United Kingdom 		 
11:15  OR9.4 - Consideration for Rare Diseases in Drug Reimbursement Decision-Making
Sheena Gosain, Canada 		 
11:30  OR9.5 - Do drug product changes have an impact on hospital treatment? A first Health Technology Assessment
Rainer Reidel, Germany 		 
11:45   OR9.6 - A conceptual and methodological framework for value assessment of medical technologies using Multiple Criteria Decision Analysis
Aris Angelis, United Kingdom 		  

Monday, June 16

Roosevelt Room

13:45-15:15
 OR010 - PATIENT PREFERENCES AND OUTCOMES
Moderator: Marisa Santos, Brazil
13:45  OR10.1 - Attitudes toward Ethical Dilemmas in Genetic Testing among Medical Students in China
JianWei Shi, China 		 
14:00  OR10.2 - Valuable tools for patients in the treatment of Type 1 diabetes? When treatment satisfaction matters
Sophie Söderholm Werkö, Sweden 		 
14:15  OR10.3 - Use of Patient-Reported Outcomes among Patients with Rare Lysosomal Storage Diseases: A Systematic Survey of the Literature
Patricia A Miller, Canada 		 
14:30  How essential hypertensive patients assess different endpoints of their treatment? An elicitation of patients’ preferences by Analytic Hierarchy Process (AHP)
Charalabos Markos Dintsios, Germany 		 
14:45  OR10.5 - Patient Reported Outcomes Monitoring (PROM) for cardiac ablative techniques
Hannah Patrick, United Kingdom 		 
15:00  OR10.6 -Patient Preferences: Understanding Risk-Benefit Trade-Offs of Genomic Testing in Chemotherapy Decisions for Breast Cancer Patients
Deborah A Marshall, Canada 		 
     

Monday, June 16

Cabin John Room

13:45-15:15
 OR011 - INVOLVING THE PUBLIC AND PATIENTS IN HTA 1
Moderator: Durhane Wong-Rieger, Canada
13:45  OR11.1 - Engaging relevant publics in the HTA process: Results from a qualitative policy analysis to inform the development of a comprehensive public engagement approach
Julia Abelson, Canada 		 
14:00  OR11.2 - Patient and Public Involvement in Health Technology Assessment: Experiences from the World and Propositions for Its Increase in Brazil
Aline Silveira Silva, Brazil 		 
14:15  OR11.3 - Involving healthcare service users in developing information material to present HTA report and recommendations
Mylene Tantchou Dipankui, Canada 		 
14:30  OR11.4 - Integrating patients’ perspectives, context, and implementation in the assessment of complex health technologies
Ansgar Gerhardus, Germany 		 
14:45  OR11.5 - Patient and public involvement in agenda setting and prioritization of HTA and systematic reviews: The Norwegian experience
Gro Jamtvedt, Norway 		 
15:00  OR11.6 - GRIPP 2: Developing consensus on the reporting of patient and public involvement for HTA
Sophie Staniszewska, United Kingdom 		 
     

Monday, June 16

Renwick + Bulfinch Room

13:45-15:15
 OR012 - INVOLVING THE PUBLIC AND PATIENTS IN HTA 2
Moderators: Janet Wale, Australia & David Grainger, Australia
13:45  OR12.1 - Towards an embedded role for patients and caregivers in the life cycle of orphan therapies
Andrea Lynn Dunn, Canada 		 
14:00  OR12.2 - Multi-stakeholder partnership as a tool of citizens’ empowerment to build a participatory HTA model in Italy
Gaudioso Antonio, Italy 		 
14:15  OR12.3 - Patients, empowerment and HTA
Helle Ploug Hansen, Denmark 		 
14:30  OR12.4 - Patient and public involvement (PPI) and engagement in early awareness and alert (EAA) activities in England
Kathryn Miles, United Kingdom 		 
14:45  OR12.5 - Developing MEET – Innovative training about HTA for patient leaders
Corina W. Ramers-Verhoeven, The Netherlands 		 
15:00  OR12.6 - Strengthening public engagement for HTA decision making in Ontario: Results from a stakeholder dialogue
Julia Abelson, Canada 		 
     

Monda y, June 16

Latrobe Room

13:45-15:15
 OR013 - SYSTEMATIC REVIEWS OF SELECTED INTERVENTIONS #2
Moderator: Helene Karcher, United Kingdom
13:45  OR13.1 - Challenges to the systematic review of sexual health interventions for people with severe mental illness
Eva Kaltenthaler, United Kingdom 		 
14:00  OR13.2 - Effectiveness of treatments for multiple chemical sensitivity: Systematic review
Marjukka Mäkelä, Finland 		 
14:15  OR13.3 - Systematic review and meta analysis of ultrasonography versus HVPG for portal hypertension
Gaeun Kim, Korea 		 
14:30  OR13.4 - A systematic review of sexual health risk reduction interventions for people with severe mental illness
Abdullah Pandor, United Kingdom 		 
14:45  OR13.5 - Value of Education Program for Children with Asthma : a Systematic Review and  Meta-Analysis
Gaeun Kim, Korea 		 
15:00  OR13.6 - Use of Autologous Fat Grafting for Reconstruction Post-Mastectomy and Breast Conserving Surgery: a Systematic Review and Meta-Analysis of Oncological Outcomes
Riaz A Agha, United Kingdom 		 
     

Monday, June 16

Burnham Room

13:45-15:15
 OR014 - PRODUCING AND USING HTA
Moderator: Alexandre Lemgruber
13:45  OR14.1 - Rocking the Boat: Social Media’s Impact on Producers and Users of HTA
Janice Mann, Canada 		 
14:00  OR14.2 - Do are the economists working with HTA in Brazil?
Giacomo Balbinotto Neto, Brazil 		 
14:30  OR14.4 - Characterization of the interaction between hospital-based HTA programs and HTA activities at national and regional levels in AdHopHTA-partner countries
Helene Arentz-Hansen, Norway 		 
14:45  OR14.5 - Medical equipment management qualification in Brazilian healthcare networks
Amanda Cristianem, Brazil 		 
15:00  OR14.6 - The Incorporation of new technologies in Brazil: the advances of CONITEC in the last two years
Vania Cristina Canuto, Brazil 		 
     

Monday, June 16

Farragut Square Room

13:45-15:15
 OR015 - METHODOLOGICAL CONSIDERATION IN HTA
Moderator: Alicia Granados, Spain
13:45  OR15.1 - Exploring psychometric properties of the SF-6D, a preference-based health-related quality of life measure, in the context of spinal cord injury
Lidia Engel, Canada 		 
14:00  OR15.2 - Selection and review of evidence for cost-effectiveness models within HTA
Eva Kaltenthaler, United Kingdom 		 
14:15  OR15.3 - Production of economic opinions on drugs and medical devices in France: challenges and issues
Clémence Thébaut, France 		 
14:30  OR15.4 - Using Equivalent Income Concept in Blood Pressure Lowering Drugs Assessment: How to Include Inequality Aversion in Cost/Benefit Analysis?
Clémence Thébaut, France 		 
14:45  OR15.5 - Examining Exclusion Criteria in National Health State Valuation Studies: a Systematic Review
Lidia Engel, Canada 		 
15:00  OR15.6 - Brazilian Methods for Data Quality Control during National EQ5D-3L Valuation. Results from QALYBrasil Project
Monica A. Cintra, Brazil 		 
     

Monday, June 16

Lafayette Park Room

13:45-15:15
 OR016 - HOSPITAL-BASED HTA #2
Moderator: Marco Marchetti, Italy
13:45  OR16.1 - The impact of hospital based reports on medical devices of Unità di Valutazione delle Tecnologie (UVT)
Carmen Furno, Italy 		 
14:00  OR16.2 - Hospital-based HTA: Current evidence and challenges
Marie-Pierre Gagnon, Canada 		 
14:15  OR16.3 - Is there a match between hospital-based HTA practices and best practices in HTA?
Marcelo Soto, Spain 		 
14:30  OR16.4 - Systematic review of the informational needs of hospital managers on investments in health technologies
Anne Mette Oelholm, Denmark 		 
14:45  OR16.5 - Reimbursement policies, hospital features and innovation in healthcare. The case of transcatheter aortic valve implantation in Italy
Aleksandra Torbica, Italy 		 
15:00  OR16.6 - A systematic approach to define a framework for best practices in Hospital based Health Technology Assessment
Lucile Danglas, Spain 		 
     

Monday, June 16

Franklin Square Room

13:45-15:15
 OR017 - DISINVESTMENT
Moderator: Janet Hiller, Australia
13:45  OR17.1 - Serendipitous disinvestment: Horizon scanning for disinvestment opportunities
Linda Mundy, Australia 		 
14:00  OR17.3 - Action Proposals for Obsolete Medical Devices - Disinvestment in the Brazilian Public Health System
Eduardo Coura Assis, Brazil 		 
14:15  OR17.4 - A rational disinvestment towards a strategic re-allocation: the debate in the Italian Health Policy Forum
Americo Cicchetti, Italy 		 
14:30  OR17.5 - MIDDIR – Methods for investments/disinvestments and distribution of health technologies in Italian Regions
Paolo Giorgi Rossi, Italy 		 
     

Monday, June 16

McPherson Square Room

13:45-15:15
 OR018 - HTA OF MEDICAL DEVICES
Moderator: Rod Taylor, United Kingdom
13:45  OR18.1 - Comparison of methods of value engineering and multi-criteria evaluation – applied to vital signs monitors
Ivana Jurickova, Czech Republic 		 
14:00  OR18.2 - Prioritization, selection and procurement of medical devices within low- and middle-income countries: outcomes of a systematic review
Karin Daniela Diaconu, United Kingdom 		 
14:15  OR18.3 - Development of a modular design applied to dialysis equipment
Flavio Fogliatto, Brazil 		 
14:30  OR18.4 - Multi-criteria decision making as a tool in medical devices assessment
Ivana Jurickova, Czech Republic 		 
14:45  OR18.5 - Health Technology Assessment for driving innovations towards best performing fields: the case of robot-assisted Surgery
Matteo Ritrovato, Italy 		 
 15:00  OR18.6 - The prioritisation of medical devices and opportunities for HTA in low- and middle-income settings: findings from two qualitative investigations
Karin Daniela Diaconu, United Kingdom 		 
     

Monday, June 16

Roosevelt Room

15:45-17:15
OR019 - ECONOMIC ANALYSIS OF SELECTED INTERVENTIONS #2
Moderator: Rabia Kahveci, Turkey
15:45  OR19.1 - The Economic Impact of Drug Eluting Balloons for Patients with Femoral-Popliteal Artery Disease
Bharati Manda, Italy 		 
16:00  OR19.2 - Cost-effectiveness evaluation of novel care pathways in glaucoma diagnosis using imaging technologies
Katie Banister, United Kingdom 		 
16:15  OR19.3 - How to Choose the Best Biological Treatment for Rheumatoid Arthritis? Effectiveness and Costs
Juliana Alvares, Brazil 		 
16:30  OR19.4 - Cost-effectiveness analysis of vemurafenib compared to dacarbazine for the metastatic melanoma treatment in Brazilian Public Health System
Telma Rodrigues Caldeira, Brazil 		 
16:45  OR19.5 - Model-based projection of clinical effectiveness and cost effectiveness of catheter-based renal denervation in moderate treatment-resistant hypertension
Jan Benjamin Pietzsch, USA 		 
 17:00  OR19.6 - Economic evaluation of oxytocin in Uniject injection system versus standard use of oxytocin for the prevention of postpartum hemorrhage in Latin America and the Caribbean
Andres Pichon-Riviere, Argentina 		 
     

Monday, June 16

Cabin John Room

15:45-17:15
OR020 - EVALUATION OF SELECTED INTERVENTIONS
Moderators: Gert Jan van der Wilt, The Netherlands & Sarvashni Moodliar, South Africa
15:45  OR20.2 Cardiovascular Exams in a Pediatric Population Assisted by a Non-Profit Private Healthcare Organization in Brazil
Silvana Marcia Bruschi Kelles, Brazil 		 
16:00  OR20.3 - The Effectiveness of Artificial Urinary Sphincter Implantation: a Retrospective Analysis from 2004 to 2011
Silvana Marcia Bruschi Kelles, Brazil 		 
16:15  OR20.4 - Proton therapy for cancer in Northeast Brazil
Maria Corina Amaral Viana, Brazil 		 
16:30  OR20.5 - Recent Trends in Multiple Sclerosis-Related Health Technology Assessment Decisions: an Assessment of Five Countries
Erin Ann Zagadailov, USA 		 
 16:45  OR20.6 - Natalizumab retention rates in Multiple Sclerosis (MS) in Brazil: a retrospective descriptive cohort study
Ivan Ricardo Zimmermann, Brazil 		 
     

Monday, June 16

Renwick + Bulfinch Room

15:45-17:15
OR021 - RARE DISEASES
Moderators: Franz Pichler, United Kingdom & Glacomo Balbinotto
15:45  OR21.1 - Access to therapies for rare diseases in Canada: the role of HTA, safety nets, and one-offs
Derek Lee Clark, Canada 		 
16:00  OR21.2 - Is It Possible to Demonstrate Cost Effectiveness of Ultra-Orphan Therapies Within Current Thresholds? Lesson Learned from Published HTAs and Studies
Saurabh(Rob) Aggarwal, USA 		 
16:15  OR21.3 - Assessment of medicines for rare conditions and end of life care: Experience of a rapid review by the Scottish Medicines Consortium
Ailsa Brown, United Kingdom 		 
16:30  OR21.4 - Economic evaluation in the context of rare diseases: is this possible?
Everton Nunes Silva, Brazil 		 
16:45  OR21.5 - Value assessments for orphan drugs: a systematic comparison of HTA decision-making processes across countries
Elena Nicod, United Kingdom 		 
 17:00  OR21.6 - Methodological development of a comprehensive MCDA framework based on real life issues in appraisal of treatments for rare diseases
Monika Wagner, Canada 		 
     

Monday, June 16

Latrobe Room

15:45-17:15
OR022 - IMPROVING HTA METHODS
Moderator: Anna Nachtnebel, Austria
15:45  OR22.2 - A decisional strategy to determine the appropriate measure to prevent contrast-induced nephropathy
Marc Rhainds, Canada 		 
16:00  OR22.3 - Producing rapid assessments of “other technologies” in European collaboration – experiences from Work Package 5, Strand B of EUnetHTA JA2
Anna Nachtnebel, Austria 		 
16:15  OR22.4 - Optimising the use of data in modelling the cost-effectiveness of acupuncture: Methodological opportunities and Challenges
Helen Weatherly, United Kingdom 		 
16:30  OR22.5 - Identifying complications of interventional procedures from national routine healthcare databases: a review of Methods
Hannah Patrick, United Kingdom 		 
 16:45  OR22.6 - Improving rapid access to reports of RCTs in Embase:  innovative methods to enhance the Cochrane Central Register of Controlled Trials (CENTRAL)
Julie May Glanville, United Kingdom 		 
     

Monday, June 16

Burnham Room

15:45-17:15
OR023 - DEVELOPMENT OF GUIDANCE
Moderator: Amarpreet S. Chawla, USA
15:45  OR23.1 - Methodological guidelines for the clinical development of dressings
Fabienne Quentin, France 		 
16:00  OR23.2 - SkillScribe™: An Innovative Electronic Platform for the Development and Distribution of Educational Programming
Matt Simpson, Canada 		 
16:15  OR23.3 - Health System Guidance Appraisal -  Better Guidance for Better Health Systems
Denis Ako-Arrey, Canada 		 
16:30  OR23.4 - A collaborative approach to guideline development
Liz Avital, United Kingdom 		 
16:45  OR23.5 - Searching for the development of Diagnostic Guidance at the National Institute for Health and Care Excellence in the UK
Jenny Kendrick, United Kingdom 		 
 17:00  OR23.6 - The ghost in the machine: the role of the expert in the production of evidence-based guidance
Hanna Patrick, United Kingdom 		 
     

Monday, June 16

Farragut Square Room

15:45-17:15
OR024 - IMPACT ON HEALTH CARE SYSTEMS
Moderator: Sean Tunis, USA
15:45  OR24.1 - Pay for performance in Brazil: an initial assessment of the Program Improving Access and Quality in Primary Care of Brazilian Ministry of Health
Jorge Maia Barreto, Brazil 		 
16:00  OR24.2 - Real life treatment costs of Telaprevir in a tertiary hospital setting in Brazil
Rodrigo Martins Abreu, Brazil 		 
16:15  OR24.3 - Coverage with evidence development: Bronchial Thermoplasty, a case study
Hannah Patrick, United Kingdom 		 
16:30  OR24.4 - Indirect Costs of Rheumatoid Arthtiris, Crohn’s Disease and Psoriasis in Poland. Results of Move to Work (M2W) Study
Barbara Gad, Poland 		 
16:45  OR24.5 - Expenditures on the Treatment of Osteoporosis in the Elderly in Brazil (2008-2010): Analysis of Associated Factors
Erika Barbosa Camargo, Brazil 		 
 17:00  OR24.6 - Patterns of Generic and Proprietary Prescribing of Proton Pump Inhibitors (PPIs) Over Time in England
Katherine Anne Hamilton, United Kingdom 		 
     

Monday, June 16

Lafayette Park Room

15:45-17:15
OR025 - (DIVERSE PERSPECTIVES ON) SYSTEMATIC REVIEW
Moderator: Marianne Klemp, Norway
15:45  OR25.1 - A review on the economic evaluations of factor VIII/IX for prophylaxis in hemophilia: what do we know and where do we go from the health technology assessment (HTA) perspective?
Cindy Gao, USA 		 
16:00  OR25.3 - Challenges for systematic review of nonanimal research
Xin Mu, China 		 
16:15  OR25.4 - Pitfalls in systematic reviews of interventions in the elderly and frail elderly
Sigurd G Vitols, Sweden 		 
16:30  OR25.5 - Development of search strategies for systematic reviews: objective versus conceptual approach
Siw Waffenschmidt, Germany 		 
 16:45  OR25.6 - Ophthalmic prostaglandin analogues for ocular hypertension or primary open-angle glaucoma: a systematic review and network meta-analysis
Yingjiao Zhao, Singapore 		 
     

Monday, June 16

Franklin Square Room

15:45-17:15
OR026 - VALUING HEALTH: PAST, PRESENT, AND FUTURE
Moderators: Kun Zhao & Steve Pearson, USA
15:45  OR26.1 - Valuing health in the UAE: an investigation of the feasibility and cultural appropriateness of using the TTO and DCE methods to generate health state values
Manny Papadimitropolous, United Kingdom 		 
16:00  OR26.2 - Did the economic reform affect the equity of health resources distribution in China? A national study in 1970-2010
Yuan Huang, China 		 
16:15  OR26.3 - Judicialization of the Right to Health
Ana Perez, Uruguay 		 
16:30  OR26.4 - Interventions for Ultra-Rare Disorders (URDs):  How to Assess “Value for Money”?
Michael Schlander, Germany 		 
16:45  OR26.5 - The Economics of Rare Diseases: Theory and Regulation
Giácomo Balbinotto, Brazil 		 
 17:00  OR26.6 - What Could the Future Hold? Simulating the Demand for Osteoarthritis ((OA) Care in Alberta to Plan a Sustainable OA Care System
Deborah A Marshall, Canada 		 
     

Monday, June 16

McPherson Square Room

15:45-17:15
OR027 - BEST PRACTICES TO OPTIMIZE RESOURCE ALLOCATION
Moderator: Alicia Granados, Spain
15:45  OR27.1 - Liaison Officers – CADTH’s “boots on the ground”
Gabrielle Zimmermann, Canada 		 
16:00  OR27.2 - The Influence of FDA and EMA Risk Management Requirements on Reimbursement Outcomes
Rachel Catherine Sliman, USA 		 
16:15  OR27.3 - Impact of multidisciplinary group practices in primary care on Efficiency – Evaluation of a French experiment of integrated primary care organization
Julien Mousquès, France 		 
16:30  OR27.4 - Let there be light: Fit for purpose methodologies to support decision-making regarding health technology
Wija Oortwijn, Netherlands 		 
 17:00  OR27.6 - Is MCDA the future of HTA in the Americas?
Mireille M.Goetghebeur, Canada